@article{e8bc3d9bf10a447e9b7e340255cc3649,
title = "Associations between Atrial Arrhythmias and Brain Amyloid Deposition: The ARIC-PET Study",
abstract = "The aim of this study is to determine if there is an association between atrial arrhythmias and brain amyloid-β (Aβ), measured on florbetapir (FBP) PET. 346 nondemented participants from the Atherosclerosis Risk in Communities study underwent FBP-PET, 185 also wore Zio{\textregistered} XT Patch. The associations between global cortical Aβ (>1.2 standardized uptake value ratio) and history of atrial fibrillation, zio-defined atrial tachycardia and premature atrial contractions, each, were evaluated. Among nondemented community-dwelling older adults, we did not find an association between atrial arrhythmias and Aβ. Other brain pathology may underlie the association described between atrial arrhythmias and cognition.",
keywords = "Arrhythmias, atrial fibrillation, cognitive impairment, imaging",
author = "Johansen, {Michelle C.} and Wendy Wang and Zhang, {Michael J.} and Alvaro Alonso and Wong, {Dean F.} and Gottesman, {Rebecca F.} and Chen, {Lin Y.}",
note = "Funding Information: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by NHLBI contracts (HHSN268201700001I, HHSN26 8201700002I, HHSN268201700003I HHSN268201 700005I, HHSN268201700004I). The ARIC-PET study is funded by the NIA (R01AG040282, previously to RG). Avid Radiopharmaceuticals provided the florbetapir isotope for the study, but had no role in the study design or interpretation of results. Dr. Johansen receives funding from the NINDS (K23NS 112459); Dr. Gottesman received prior funding from the NIA (K24AG052573). Dr. Alonso receives funding from the NIH (K24HL148521, P30AG066 511). Dr. Chen receives funding from the NIH (R01H L126637, R01HL141288, and K24HL155813) iRHYTHM (the manufacturer of Zio{\textcopyright}XT) did not contribute any funding nor to analysis or drafting of the manuscript in any way. Funding Information: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by NHLBI contracts (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I HHSN268201700005I, HHSN268201700004I). The ARIC-PET study is funded by the NIA (R01AG040282, previously to RG). Avid Radiopharmaceuticals provided the florbetapir isotope for the study, but had no role in the study design or interpretation of results. Dr. Johansen receives funding from the NINDS (K23NS112459); Dr. Gottesman received prior funding from the NIA (K24AG052573). Dr. Alonso receives funding from the NIH (K24HL148521, P30AG066511). Dr. Chen receives funding from the NIH (R01HL126637, R01HL141288, and K24HL155813). Publisher Copyright: {\textcopyright} 2022-IOS Press. All rights reserved.",
year = "2022",
doi = "10.3233/JAD-215378",
language = "English",
volume = "86",
pages = "43--48",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
number = "1",
}